A prevalence-incidence mixture model for interval-censored screening and post-treatment surveillance data in a population with a temporarily increased disease risk

Running title: Prevalence-incidence mixture model

Authors and affiliations:

Kelsi R. Kroon*[1,2] , Johannes A. Bogaards[1,2] , Johannes Berkhof[1,2, 3]

[1] Department of Epidemiology and Data Science, Amsterdam UMC, location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, the Netherlands
[2] Amsterdam Public Health Research Institute, Methodology, Amsterdam, the Netherlands
3 Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands

* Corresponding Author:

Kelsi R Kroon (k.kroon@amsterdamumc.nl, ORCiD: 0009-0005-7546-4410)

Address: Department of Epidemiology and Data Science, Amsterdam UMC – location Vrije Universiteit, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands

Data availability: The data that support the findings of this study are available from the corresponding author upon reasonable request. The code for the accompanying R package is publicly available on GitHub (https://github.com/kelsikroon/PI3M).

Funding: This work was supported by the Horizon 2020 research and innovation program of the European Commission (RISCC project, grant agreement No 847845) (to KRK, JAB, and JB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest: KRK, JAB, and JB declare no conflicts of interests.

Ethics approval and consent to participate: The POBASCAM trial (Trial registration ID: NTR218) was approved by the Medical Ethics Committee of the VU University Medical Centre (Amsterdam, The Netherlands; no. 96/103) and the Ministry of Public Health (The Hague, The Netherlands; VWS no. 328650). All participants provided written informed consent. The post-treatment cohort study (Trial registration ID: NTR1468) was approved by the ethics board at all hospitals. All participants provided written informed consent.

Authors' contributions: KRK: Conceptualization, Formal analysis, Methodology, Visualisation, Writing - Original Draft Preparation; **JAB**: Conceptualization, Supervision, Writing - Reviewing and Editing; **JB**: Conceptualization, Supervision, Writing - Reviewing and Editing. All authors gave final approval of the submitted version of the manuscript. The work reported in the paper has been performed by the authors, unless clearly specified in the text.

Acknowledgements: The authors thank C JLM Meijer for providing the POBASCAM data.

Abstract

To optimize screening and surveillance programs, it is essential to have information on the

duration between the onset of a high-risk condition and treatable disease. Modelling of this

duration is complicated when the high-risk condition only applies to some of the subjects

and/or is temporary (e.g., oncogenic infections). Additionally, interval-censored data

between visits makes exact disease onset time unknown and some of the disease cases may

already be present at baseline. We propose a prevalence-incidence mixture model for

interval-censored data to estimate cumulative disease risk based on individual risk factors

and to estimate the mean duration of the high-risk condition. Subjects without the high-risk

condition may also develop disease which is modelled by adding background risk.

Parameters are estimated with an Expectation-Maximisation (EM) algorithm with weakly

informative Cauchy priors. The duration between the baseline high-risk condition and

treatable disease is directly obtained from the model. A score test is derived to check for

poor fit. The algorithm is validated through simulation studies and applied to Dutch cervical

cancer screening and post-treatment surveillance data. The screening example is

longitudinal data of women who tested positive for human papillomavirus (HPV) at baseline.

Some of these had undiagnosed, treatable disease (CIN2+) at baseline, some developed

CIN2+ during follow-up, and some were assumed to clear the infection. The second example

is surveillance data of women treated for CIN2+. They either had residual CIN2+ at baseline,

were HPV-infected (without CIN2+) despite the treatment or were HPV-uninfected. The HPV

and disease status at baseline were not observed. Our EM algorithm showed very good

convergence for simulated data and the parameter estimates were close to the true values

for realistic sample sizes. In the examples, our model had lower Akaike's Information

Criterion values than models with Weibull, B-spline and lognormal hazards for incident

events (difference 0.7 to 26.7). To conclude, our prevalence-incidence mixture model can

provide an accurate fit to the data and can be used for designing risk-based screening and

surveillance programs.

Keywords: cumulative risk estimation; EM algorithm; interval censoring; mixture model;

screening data

1. Introduction

In public health and medical research, prediction models play a crucial role in identifying individuals who are at highest risk of developing a disease. In screening and post-treatment surveillance, there are two potential scenarios for disease detection. Individuals who are screen-positive or treated for disease may have underlying *prevalent* disease at baseline, or disease might develop in-between two visits (*interval-censored incident disease*). Furthermore, incident disease can develop either from the baseline condition or from a newly acquired condition during follow-up. The baseline condition may only apply to a proportion of subjects and may be temporary so that the cumulative disease risk is likely to level off.

A motivating example is human papillomavirus (HPV) infections, which cause almost all cervical cancers worldwide[1] and are also associated with several other cancers and warts[2]. After an initial HPV infection, individuals are at increased risk of developing a high-grade cervical lesion (CIN2+) until the infection clears. To optimize a cervical cancer screening or post-treatment surveillance program, it is essential to estimate the duration between the high-risk condition and CIN2+.

Non-parametric and parametric models have widely been used for estimating the cumulative risk but they have limitations when applied to our setting. Non-parametric cumulative incidence models[3–6] assume that there are no prevalent disease cases. This can be accounted for by defining a very small interval with a left bound of zero[7]. However, a non-parametric model does not have covariates which are crucial when designing risk-based screening or surveillance programs. Parametric models allow for more flexibility with respect to the modelling of the effects of covariates. Prevalence-incidence mixture models have been proposed[7,8] which assume a logistic regression model for prevalent disease, some of which are undiagnosed at baseline, and a parametric model (e.g. Weibull) for incident disease. These models may provide an accurate fit of the incidence function, but do not provide credible estimates of the mean time to incident disease. This is because they assume that the cumulative incidence approaches 1 for large time T whereas the observed incidence is typically low in screening and post-treatment surveillance settings. A reason for the low incidence is that only a proportion of the subjects without prevalent disease at

baseline have a high-risk baseline condition[9]. For example, in post-treatment surveillance

studies, subjects are at high risk of a recurrent lesion when not all causative cells were

removed by the treatment. Furthermore, the high-risk condition may be temporary, for

example, because a competing event prevents progression from the high-risk condition to

disease. If the competing event is observed during follow-up, then a prevalence-incidence

competing risk model can be specified[10]. However, there are several situations where such a

model cannot be applied. For example, in screening studies the competing state is not

measured during follow-up when follow-up is done in accordance with national guidelines

and the new screening instrument has not yet been implemented.

We propose to capture the heterogeneity in the data through a prevalence-incidence

mixture model where a proportion of prevalent disease cases is undiagnosed at baseline

and subjects without prevalent disease have a temporarily increased disease risk that

converges with the background risk over time. Incident cases developed from the baseline

condition are assumed to follow a mixture of an exponential distribution and non-

progressive condition, whereas other incident disease cases are described by adding

background risk. The model for incident disease developed from the baseline condition is

mathematically equivalent to a model with an exponential time distribution for two

competing events, of which one is not observable[11]. To examine whether the model is

violated by the data, we present a score test comparing the exponential distribution for

incident disease from the baseline condition against a Gamma alternative.

The article is structured as follows. In Section 2, we describe the model and an expectation-

maximisation (EM) algorithm for estimating the model parameters with interval-censored

screening data, which has been implemented in an R package. In Section 3, we present

simulation studies to verify that the algorithm can accurately recover true parameter values

and a score test to check the exponential distribution for incident disease from the baseline

condition. In Section 4, we apply the model to estimate the cumulative risk of CIN2+ in two

different data sets. The first dataset consists of cytological and histological follow-up of a

screening population of women who tested positive for HPV at baseline. Some of these

women had undiagnosed CIN2+ at baseline, some developed CIN2+ during follow-up and

some were assumed to clear the infection. The second dataset consists of cytological and

histological follow-up of a cohort of patients who were treated for CIN2+ at baseline. Some

of these women had (undiagnosed) residual CIN2+ at baseline, some were assumed to be

HPV-infected despite the treatment and were at high risk of developing recurrent CIN2+

during follow-up, and some were assumed to be HPV-uninfected at baseline. The HPV status

at baseline was not measured. Finally, in Section 5 we conclude and discuss our findings.

2. Model

Due to the nature of screening programs and disease surveillance, the exact time of onset of

disease is not observed. Instead, there is only an interval of the last time an individual with

the baseline condition was observed without the disease, and the first time that the disease

was detected. If the disease did not develop during follow-up, this interval will be right-

censored. Further, some individuals are immediately referred at baseline, therefore it can

be determined whether the disease is present at baseline. However, some individuals are

not referred at baseline but the disease is detected at their first visit, in which case it is

unknown whether the disease was present at baseline.

For individuals $i = 1, \dots, n$ who have an elevated risk due to a baseline condition, let $(L_i, R_i]$

be the interval when the disease develops, where L_i is the last time the ith individual was

observed without disease and R_i is the first time that disease is detected for the ith

individual. We allow $R_i = \infty$ to include individuals who do not develop disease during

follow-up. Let z_i be an indicator variable for prevalent disease at baseline (where $z_i = 1$

means that the disease was present at baseline), which, as described above, is unknown for

some individuals. Let $\boldsymbol{\theta}_1, \boldsymbol{\theta}_2$ be disjoint vectors of parameters, and let $\boldsymbol{x}_1$ and $\boldsymbol{x}_2$ be subject-

specific vectors of covariates for prevalence and progression respectively. Let $\pi(\boldsymbol{x}_1; \boldsymbol{\theta}_1)$ be

the probability of having the disease at baseline (prevalent disease). Then the probability

that the disease has developed before time t, i.e. the time to disease, denoted by T, lies in

$[0, t)$, is a mixture distribution given by

$$P(T \leq t; \boldsymbol{x}_1, \boldsymbol{x}_2, \boldsymbol{\theta}_1, \boldsymbol{\theta}_2, \lambda_2, \beta) = \pi(\boldsymbol{x}_1, \boldsymbol{\theta}_1) + \left(1 - \pi(\boldsymbol{x}_1, \boldsymbol{\theta}_1)\right) F(t; \boldsymbol{x}_2, \boldsymbol{\theta}_2, \lambda_2, \beta) \# \qquad (1)$$

where $F(t; \boldsymbol{x}_2, \boldsymbol{\theta}_2, \lambda_2, \beta)$ is the cumulative risk of incident disease. Among incident cases

there are two independent causes, disease can either develop from the baseline condition

or from another condition (e.g. a new infection acquired after baseline). Events from the

baseline condition follow a competing events framework, where the baseline condition

either progresses to the disease or transitions to an unobservable, competing state, both of

which are assumed to follow an exponential distribution.

Let us assume a competing risk framework with progression parameter $\lambda_1(x_2, \theta_2)$ and

clearance parameter λ_2. Then the cumulative risk of developing disease from the baseline

condition at time t is given by

$$G(t; x_2, \theta_2, \lambda_2) = \frac{\lambda_1(x_2, \theta_2)}{\lambda_1(x_2, \theta_2) + \lambda_2} \big(1 - \exp(-(\lambda_1(x_2, \theta_2) + \lambda_2)t)\big). \tag{2}$$

In this specification, $\delta(x_2, \theta_2) = \lambda_1(x_2, \theta_2)/(\lambda_1(x_2, \theta_2) + \lambda_2)$ is the probability of

disease during follow-up developed from the baseline high-risk condition. The expected

time from the high-risk condition and the event is given by $1/(\lambda_1(x_2, \theta_2) + \lambda_2)$. So far, we

assumed that all subjects have a high-risk condition at baseline, but the model can also be

applied when it is not known who is at high-risk of developing disease. In this situation, only

a proportion of the subjects have a high-risk condition and either develop disease or

transition to a competing, unobservable event. The expected duration from the high-risk

condition to disease is still given by $1/(\lambda_1(x_2, \theta_2) + \lambda_2)$, but $\delta(x_2, \theta_2)$ is now the

proportion of subjects who have a high-risk condition and develop disease from this high-

risk condition. The progression parameter $\lambda_1(x_2, \theta_2)$ can in both situations be interpreted

as the derivative of the cumulative incidence $G(t; x_2, \theta_2, \lambda_2)$ at $t = 0$, i.e. $G'(0; x_2, \theta_2, \lambda_2)$.

For events that do not develop from the baseline condition, we define the cumulative

background risk of developing disease, $H(t; \beta)$, given by:

$$H(t; \beta) = 1 - \exp(-\beta t) \tag{3}$$

137 where β is the background hazard. Now, we get the following model for incident disease:

$$F(t; x_2, \theta_2, \lambda_2, \beta) = G(t; x_2, \theta_2, \lambda_2) + [1 - G(t; x_2, \theta_2, \lambda_2)]H(t; \beta). \tag{4}$$

138 The model allows for the inclusion of baseline covariates for the prevalence parameter and

139 the rate parameter $\lambda_1(x_2, \theta_2)$. For the proportion of prevalent disease, $\pi(x_1, \theta_1)$, a logistic

140 regression model is used to include covariates:

$$\text{logit}\big(\pi(x_1, \theta_1)\big) = \theta_{1,0} + \theta_{1,1}x_{1,1} + \cdots + \theta_{1,m_1}x_{1,m_1}, \tag{5}$$

141 where m_1 is the number of covariates included in the logistic model for prevalent disease.

142 For both λ_1 and λ_2, a log transformation is used in which case the covariates for λ_1 have a

143 proportional effect on its hazard:

$$\log\big(\lambda_1(\boldsymbol{x_2}, \boldsymbol{\theta_2})\big) = \theta_{2,0} + \theta_{2,1}x_{2,1} + \cdots + \theta_{2,m_2}x_{2,m_2}, \tag{6}$$

where m_2 is the number of covariates used for the rate parameter λ_1.

In principle, the background risk β can also be linked to covariates, but this is not considered

here as its regression coefficients tend to be less well identified as those of π and λ_1. The

main role of β is to describe how the baseline hazard is influenced by the risk of an event

that did not develop from the baseline condition.

In our model, the regression coefficient $\theta_{2,i}$ $(i \geq 1)$ can also be interpreted as the change in

the log-odds of progression probability $\delta(\boldsymbol{x_2}, \boldsymbol{\theta_2})$ associated with a one-unit increase in the

corresponding covariate. To see this, let $\log\big(\lambda_1(\boldsymbol{x_2}, \boldsymbol{\theta_2})\big) = \theta_{2,0} + \sum_{i=1}^{m_2} \theta_{2,i}x_{2,i} =$

$\gamma(\boldsymbol{x_2}, \boldsymbol{\theta_2})$, and $\log(\lambda_2) = \phi$. Then:

$$\delta(\boldsymbol{x_2}, \boldsymbol{\theta_2}) = \frac{\lambda_1(\boldsymbol{x_2}, \boldsymbol{\theta_2})}{\lambda_1(\boldsymbol{x_2}, \boldsymbol{\theta_2}) + \lambda_2} = \frac{e^{-\phi + \gamma(\boldsymbol{x_2}, \boldsymbol{\theta_2})}}{e^{-\phi + \gamma(\boldsymbol{x_2}, \boldsymbol{\theta_2})} + 1}, \tag{7}$$

so the logit is linear in the covariates: $\text{logit}\, \delta(\boldsymbol{x_2}, \boldsymbol{\theta_2}) = -\phi + \gamma(\boldsymbol{x_2}, \boldsymbol{\theta_2})$.

A variant of the traditional expectation-maximisation (EM) algorithm called the EM gradient

algorithm[12] is used to estimate the parameters. The EM gradient algorithm approximately

solves the maximisation step of the EM algorithm by using a single Newton step on the

expected log-likelihood instead of directly solving the maximisation, and it has been shown

to have similar convergence properties as the standard EM algorithm[13]. Details about the

estimation can be found in the Supplementary Appendix.

A situation might arise where there are no or a very low number of subjects with a specific

combination of a covariate and the outcome. This causes identifiability issues when

estimating the parameter for this covariate, and although the algorithm may converge, it is

likely that the confidence intervals for the parameter will be very large. To address these

issues in the logistic prevalence mixture, we choose a Cauchy distribution with a centre of 0

and scale of 2.5, as recommended by Gelman et al. (2008)[14], as a weakly informative prior.

The first and second derivatives of the log of the Cauchy$(0, 2.5)$ distribution with respect to

each parameter can be directly evaluated in the maximisation step and added to

calculations of the gradient and Hessian, respectively. Credible intervals for the parameters

in the model with a Cauchy prior can be obtained through Taylor expansion[15].

3. Simulation study

3.1 Validation of model fit

Simulation study I: setup

We assessed the performance of our model in a simulation study where data was simulated

according to the following settings. For the disease process, values for the parameters

$\boldsymbol{\theta_1}, \boldsymbol{\theta_2}, \lambda_2$ and β were set, and for each subject i, a Bernoulli random variable for prevalent

disease, P_i, was drawn with probability $\pi(\boldsymbol{x_1}, \boldsymbol{\theta_1})$. In subjects without prevalent disease (i.e.

$P_i = 0$), a second Bernoulli variable for incident disease from the baseline condition, A_i, was

drawn with probability $\delta(\boldsymbol{x_2}, \boldsymbol{\theta_2})$. Additionally, two event times were generated for incident

disease developed from the baseline condition (T_1) and from the new condition acquired

after baseline (T_2). T_1 was drawn from an exponential distribution with rate parameter

$\lambda_1(\boldsymbol{x_2}, \boldsymbol{\theta_2}) + \lambda_2$ if $A_i = 1$, and set to infinity otherwise and T_2 was drawn from an

exponential distribution with rate parameter β. We then took the minimum of T_1 and T_2 as

the onset time of incident disease, i.e., $T_D = \min(T_1, T_2)$.

Screening (or post-treatment surveillance) times were drawn from a Beta(20, 20)

distribution scaled to have a mean around 3-yearly intervals until there was at least 25 years

of follow-up. Attendance of each individual at each screening visit was drawn from a

Bernoulli distribution. This resulted in left and right intervals representing the last time an

individual was observed before disease onset and the first time after disease onset.

The following parameter values for prevalence, progression, and clearance were used for

the simulation study without covariates: $\pi = \log(0.20), \log(\lambda_1) = -1$, and $\log(\lambda_2) =$

-1.5. These parameter values were loosely based on values observed in cervical cancer

screening studies. We investigated the effect of simulation settings on model performance

by varying the (1) sample size (N=1000 or 10,000), (2) attendance probability per screening

round (0.75 or 1), (3) value of background risk ($\beta = 0, 0.005, 0.01,$ or 0.02) and (4) weakly

informative prior (none or Cauchy(0,2.5)). This resulted in 32 separate simulation
conditions.

The simulation study was repeated with baseline covariates, again loosely based on values
in cervical cancer screening studies. A continuous variable Age was generated from a
Uniform(30, 70) distribution to reflect age at baseline, and a binary variable HPV16 (e.g.,
positive for HPV genotype 16 at baseline) was generated with probability of being equal to 1
set at a 0.3. This parameter was assumed to positively affect both the prevalence and
progression probabilities in the model. The following model was used:

$$\text{logit}(\pi(\boldsymbol{x_1}, \boldsymbol{\theta_1})) = \theta_{1,0} + \theta_{1,1} \times \text{Age} + \theta_{1,2} \times \text{HPV16} \tag{8}$$
$$\log(\lambda_1(\boldsymbol{x_2}, \boldsymbol{\theta_2})) = \theta_{2,0} + \theta_{2,1} \times \text{HPV16}$$

with parameters set at: $\boldsymbol{\theta_1} = \{\theta_{1,0} = -3, \theta_{1,1} = 1, \theta_{1,2} = 1\}, \boldsymbol{\theta_2} = \{\theta_{2,0} = -1, \theta_{2,1} =$
$2\}$, and $\lambda_3 = -1.5$. All simulated data sets were fit with our EM algorithm using 10 different
random starting values per data set. For each simulation setting 200 data sets were
generated and the median estimate, the percent bias, and 95% confidence/credible interval
coverage probability (CP) were calculated (shown in Figure 1). Additionally, the time that it
takes for the algorithm to converge and the convergence rate were calculated for models
with and without covariates in the setting with low background risk ($\beta = 0.005$), imperfect
attendance probability (0.75) and priors included.

Simulation study I: results
The model performed well in percentage bias and coverage across all parameters in
simulations, regardless of covariates, attendance probability, or priors, for low background
risk (Figure 1). Without covariates, percentage bias ranged from -1.64% to 1.93% (N=1000)
and -0.42% to 0.45% (N=10,000), with coverage probability between 91.0% to 98.5%
(N=1000) and 91.0% to 98.0% (N=10,000). Percentage bias ranged between -1.45% and
1.93% at attendance probability of 0.75 and between -1.64% and 0.91% at perfect
attendance. Percentage bias ranged from -1.30% to 1.93% without priors and from -1.64%
to 0.95% with weakly informative priors. Attendance probability and inclusion of priors had
minimal impact on coverage probability. With covariates, similar trends were observed. For
N=1000, percentage bias ranged from -6.05% to 5.63%, with coverage probability between

91.0% to 99.0%. For N=10,000, the absolute percentage bias was lower than for N=1000

(<1.45% across settings), and the coverage probability ranged from 91.5% to 99.0%.

The average CPU time (in seconds) to fit each of the 200 simulated data sets increased with

covariates. Without covariates, average time was 2.42s (N=1000) and 19.77s (N=10,000),

and with covariates the average time rose to 14.96s (N=1000) and 143.85s (N=10,000).

There were no cases of non-convergence in any of the settings.

3.2 Checking exponential progression rate

Score test

The exponential progression rate for events developed from the baseline condition may be

violated by the data even after adjusting for competing, unobserved events and events that

did not develop from the baseline condition. This limits the applicability of the model when

used to support decision making for a screening or post-treatment surveillance protocol

with multiple test moments. An example is the outcome cancer developing through multiple

stages which can be described by assuming an increasing hazard since onset of the baseline

condition. We evaluated the fit of an exponential time distribution for events developed

from the baseline condition by devising a score test with a Gamma distribution as

alternative. If the progression to disease follows a Gamma distribution with shape

parameter k and rate parameter λ_1, then the cumulative incidence function for events

developed from the baseline condition becomes

$$G(t; \lambda_1, \lambda_2, k) = \frac{\lambda_1^k}{(\lambda_1 + \lambda_2)^k} \frac{1}{\Gamma(k)} \int_0^t (\lambda_1 + \lambda_2)^k u^{k-1} e^{-(\lambda_1 + \lambda_2)u} du, \tag{9}$$

which in turn is the distribution function of a Gamma variable with shape parameter k and

rate parameter $\lambda_1 + \lambda_2$ multiplied by the constant $\lambda_1^k/(\lambda_1 + \lambda_2)^k$.

The null hypothesis is that the Gamma shape parameter, k, in equation (9) equals one,

thereby reducing the Gamma distribution to an exponential distribution. To calculate the

gradient and Hessian of the log-likelihood function evaluated at $k = 1$, we used numerical

methods to obtain the first and second derivatives of $G(t)$ in equation (9) with respect to

the shape parameter. Let $\widetilde{\boldsymbol{\theta}} = \{k = 1, \widehat{\boldsymbol{\theta}}\}$ be the constrained maximum likelihood estimator

(MLE) where $\widehat{\boldsymbol{\theta}}$ is the MLE for the remaining parameters, $U(\widetilde{\boldsymbol{\theta}})$ is the score vector, and $I(\widetilde{\boldsymbol{\theta}})$

is the Fisher information matrix. Then the score test statistic is given by $(S(\widetilde{\boldsymbol{\theta}}) =$

$U(\widetilde{\boldsymbol{\theta}})^2/I(\widetilde{\boldsymbol{\theta}}))$ which is asymptotically Chi-squared distributed with 1 degree of freedom

under the null.

Simulation study II: setup

Simulation studies were performed to evaluate the power and Type 1 error of the model

under varying combinations of the (1) shape parameter, (2) background risk, and (3) sample

size. Data was generated according to the procedure described previously, however in this

case the Bernoulli variable for incident disease developed from the baseline condition, A_i,

was drawn with probability $\lambda_1^k/(\lambda_1 + \lambda_2)^k$ and T_1 was generated from a gamma distribution

with shape parameter k and rate parameter $\lambda_1 + \lambda_2$, according to equation (9). The shape

parameter was set at either $k = 1, 1.5$ or 2, where $k = 1.5$ and $k = 2$ are time distributions

with increasing hazards. Background risk was set at either $\beta = 0, 0.005, 0.01,$ or 0.02, and

was assumed to be either known and fixed at its correct value or estimated with the EM

algorithm. Sample size was either $N = 1000$ or $10,000$. This makes $2\,(N) \times 3\,(k) \times$

$3\,(\beta) = 36$ combinations in case the background risk is positive, plus $2\,(N) \times 3\,(k) = 6$

combinations in case the background risk is zero resulting in 42 combinations. Data sets

were generated for each combination until 100 data sets had a successful model fit.

Simulation study II: results

267 [Place Table 1 near here] The results are in Table 1. For N=1000, the Type I error ranges

268 from 0.03 to 0.10 and for N=10,000, it does not exceed 0.05. For N=1000, the power under k

269 > 1 ranges from 0.43 to 0.99 when k = 2 and is negligible or low when k < 2. For N=10,000,

270 the power ranges from 0.71 to 1.00.

4. Examples

4.1 Cervical cancer screening data

The Population-based screening study Amsterdam (POBASCAM) is a randomized controlled

screening trial (Netherlands trial registration ID: NTR218) in the Netherlands consisting of

women from the Dutch population recruited between 1999 and 2002, and the maximum

follow-up was 19 years. The study has been described before[16,17]. In this application, we

used a subset of 2,269 women who were HPV-positive at their first screening date

(baseline). The date of the first histology test reporting CIN2+ was set as the right bound. If

an index smear was reported within 3 months before the first CIN2+ histology diagnosis, it

was used as the right bound instead. For the left bound, the most recent normal cytological

finding and/or histological finding reporting <CIN2 occurring before the right bound was

used.

The information loss, measured by the AIC, was low for our model without covariates (AIC =

4740.12) compared to the logistic-Bspline model[7] with five knots (AIC = 4740.83), the

logistic-Weibull (AIC = 4767.84) and the logistic-lognormal model (AIC = 4747.46).

[Place Table 2 near here] Table 2 gives parameter estimates with 95% confidence intervals,

log-likelihood values and score test results for our model with abnormal baseline cytology

defined as a binary variable in the prevalent disease regression equation, and HPV16

genotype defined as a binary variable in the prevalent and incident disease regression

equations. The selection of the variables was based on HPV literature, which reported

cytology as prognostic for prevalent disease and HPV16 genotype as prognostic for

prevalent and future disease[18,19]. The score test was not significant for the models with and

without background risk. Adding background risk improved the fit of the model (LR 5.56, p-

value 0.018), and adding the Cauchy prior reduced the width of the credible intervals in the

model with background risk.

For HPV16-positive women, the mean time to CIN2+ was 3.32 years (95% CI: 2.23, 4.43) and

the proportion of women who developed CIN2+ from the baseline infection was 0.33 (95%

CI: 0.29, 0.38). For HPV16-negative women, the mean time to CIN2+ was 4.34 years (95% CI:

2.83, 5.86) and the proportion of women who developed CIN2+ from the baseline condition

was 0.13 (95% CI: 0.10, 0.16).

4.2 Cervical post-treatment follow-up data

After treatment of CIN2+, there is a chance of residual disease due to incomplete excision

(prevalent disease) or HPV infected cells (the baseline condition) regrow to CIN2+. Women

also remain at risk of developing a new CIN2+ (background risk)[20]. We used data from a

long-term multi-cohort study following women after treatment for CIN2+ (Netherlands trial

registration ID: NTR1468)[21]. This cohort study included 435 women who were monitored

with HPV testing and cytology at 6, 12, and 24 months after treatment. Thereafter, women

were followed through the routine screening programme with 5-year intervals. The
maximum follow-up was 21 years.

We compared our model without covariates to other prevalence-incidence models using
Akaike's Information Criterion (AIC). Our model (AIC = 610.13) fitted slightly better than a
logistic-Bspline model with five knots (AIC = 617.39), logistic-Weibull (AIC = 614.64) and
logistic-lognormal model (AIC = 613.48).

[Place Table 3 near here] Table 3 gives parameter estimates with 95% confidence intervals,
log-likelihood values and score test results for three models with severity of disease at
treatment as covariate (CIN3: 1 if CIN3+, 0 if CIN2) in the prevalent and incident disease
regression equations. The score test was significant for a model without background risk (p-
value = 0.0047), but was not significant when background risk was included (p-value = 0.51)
indicating that an exponential progression model for events developed from the baseline
condition and background risk for other events was not violated by the data. Adding
background risk also significantly improved model fit (LR 8.52, p-value: 0.0035), but led to
wide confidence intervals for the intercept and effect of CIN3. Smaller credible intervals
could be obtained by adding a Cauchy prior.

For women with CIN3 at treatment, the expected time to recurrence was 1.05 years (95%
CI: 0.45, 1.64) and the proportion that developed disease was 0.13 (95% CI: 0.04, 0.21). For
women with CIN2 at treatment, the expected time to recurrence was 1.11 years (95% CI:
0.50, 1.72) and the proportion that developed disease was 0.07 (95% CI: 0.00, 0.14).

5. Discussion

We present a model for a population with a heterogenous disease risk that adds to the
previously introduced concept of prevalence-incidence mixture models for the cumulative
risk of disease[7,8]. By combining concepts from this model with additional parameters, we
were able to decompose a complex process into simpler key components that together
provide accurate estimates of the cumulative disease risk compared to non-parametric
estimates.

To model progression, a competing risks framework with exponential distribution for
disease progression was used which produced cumulative incidence curves with an AIC fit
comparable to or lower than those of existing methods (i.e., Weibull, lognormal, B-splines).

A specific feature of our model is that it separates events that are caused by the baseline
condition and events that are not caused by the baseline condition. Models that do not
separate these events are less suitable when the aim is to estimate the duration from the
baseline condition and treatable disease.

Our estimated model parameters can be used in Markov simulation models that are widely
used to estimate the health gains and harms (i.e., QALYs) of new screening algorithms over
a patient's screening lifetime. Our score test can be used to detect lack of fit and hence be
used to evaluate whether a Markov simulation model is violated by the data. If the model is
consistent with the data, our model can be used to predict the impact of multiple rounds of
screening and inform changes in the screening interval when moving towards a more
personalised approach based on individual risk factors. Furthermore, our model can be used
in post-treatment surveillance settings to assess how long the disease risk exceeds the
background risk, warranting surveillance.

A limitation of our model is that it does not account for the sensitivity of the screening test
results collected after baseline. This is important when determining the left and right bound
of the interval-censored data. The bias in the cumulative incidence is expected to be small
when the sensitivity is above 0.50, but can be substantial if the screening test sensitivity is
lower[3]. Notably, the sensitivity of repeat cytology for detecting CIN2+ is about 0.85[22].

Additionally, our model, when viewed as a competing risk model, does not use follow-up
measurements from the baseline condition in order to assess clearance. Our model was
motivated by cohort studies where the baseline condition is not reassessed at follow-up
measurements. A Weibull prevalence-incidence mixture model with a clearance event was
developed by Hyun (2020)[10]. This model still assumes that the high-risk condition can be
measured without error and a possible path for future research is to account for the limited
sensitivity of the screening test for assessing the high-risk condition during follow-up. A
Bayesian prevalence-incidence mixture model was recently proposed that takes
misclassification into account due to limited sensitivity of the screening test[23]. Such an
approach, adapted to a competing risk setting, could be beneficial when analysing large
data with detailed information recorded at every visit.

In conclusion, our model provides a flexible and interpretable approach for estimating
disease risk that can be used to inform changes in the screening program and the

incorporation of individual risk factors as we move towards a more personalized approach.

Future work could explore incorporating test sensitivity of follow-up screening test results

into the model.

References

1. Walboomers JM, Jacobs M V, Manos MM, Bosch FX, Kummer JA, Shah K V, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999/08/19. 1999;189(1):12–9. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F PubMed PMID: 10451482.
2. Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018 Apr;18(4):240–54. doi:10.1038/nrc.2018.13 PubMed PMID: 29497146.
3. Witte BI, Berkhof J, Jonker MA. An EM algorithm for nonparametric estimation of the cumulative incidence function from repeated imperfect test results. Stat Med. 2017 Sep 20;36(21):3412–21. doi:10.1002/sim.7373
4. Turnbull BW. Nonparametric Estimation of a Survivorship Function with Doubly Censored Data. J Am Stat Assoc. 1974 Mar;69(345):169–73. doi:10.1080/01621459.1974.10480146
5. Turnbull BW. The Empirical Distribution Function with Arbitrarily Grouped, Censored and Truncated Data. Journal of the Royal Statistical Society: Series B (Methodological). 1976;38(3):290–5. doi:https://doi.org/10.1111/j.2517-6161.1976.tb01597.x
6. Kaplan EL, Meier P. Nonparametric-Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53(282):457–81. doi:Doi 10.2307/2281868 PubMed PMID: WOS:A1958WX09300012.
7. Cheung LC, Pan Q, Hyun N, Schiffman M, Fetterman B, Castle PE, et al. Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records. Stat Med. 2017/07/01. 2017;36(22):3583–95. doi:10.1002/sim.7380 PubMed PMID: 28660629.
8. Hyun N, Cheung LC, Pan Q, Schiffman M, Katki HA. Flexible risk prediction models for left or interval-censored data from electronic health records. Ann Appl Stat. 2017 Jun 1;11(2). doi:10.1214/17-AOAS1036
9. Srivastava S, Koay EJ, Borowsky AD, De Marzo AM, Ghosh S, Wagner PD, et al. Cancer overdiagnosis: a biological challenge and clinical dilemma. Nat Rev Cancer. 2019 Jun 25;19(6):349–58. doi:10.1038/s41568-019-0142-8
10. Hyun N, Katki HA, Graubard BI. Sample-weighted semiparametric estimation of cause-specific cumulative risk and incidence using left- or interval-censored data from electronic health records. Stat Med. 2020 Aug 15;39(18):2387–402. doi:10.1002/sim.8544
11. Titman AC, Sharples LD. Semi-Markov models with phase-type sojourn distributions. Biometrics. 2009/11/17. 2010;66(3):742–52. doi:10.1111/j.1541-0420.2009.01339.x PubMed PMID: 19912172.
12. Lange K. A Gradient Algorithm Locally Equivalent to the Em Algorithm. Journal of the Royal Statistical Society Series B-Methodological. 1995;57(2):425–37. PubMed PMID: WOS:A1995QL97000006.
13. Dempster AP, Laird NM, Rubin DB. Maximum Likelihood from Incomplete Data Via the *EM* Algorithm. J R Stat Soc Series B Stat Methodol. 1977 Sep 1;39(1):1–22. doi:10.1111/j.2517-6161.1977.tb01600.x

14. Gelman A, Jakulin A, Pittau MG, Su YS. A weakly informative default prior distribution for logistic and other regression models. Ann Appl Stat. 2008 Dec 1;2(4). doi:10.1214/08-AOAS191

15. Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian Data Analysis. Chapman and Hall/CRC; 2013. doi:10.1201/b16018

16. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer. 2004/04/01. 2004;110(1):94–101. doi:10.1002/ijc.20076 PubMed PMID: 15054873.

17. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 20111214th ed. 2012;13(1):78–88. doi:10.1016/S1470-2045(11)70296-0 PubMed PMID: 22177579.

18. Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett TR, Cheung L, Chen X, et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020 May;22:100293. doi:10.1016/j.eclinm.2020.100293

19. Inturrisi F, Rozendaal L, Veldhuijzen NJ, Heideman DAM, Meijer CJLM, Berkhof J. Risk of cervical precancer among HPV–negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study. PLoS Med. 2022 Oct 28;19(10):e1004115. doi:10.1371/journal.pmed.1004115

20. Bleeker MCG, Meijer CJLM, Berkhof J. Follow-up after treatment for cervical intraepithelial neoplasia. BMJ. 2012 Oct 31;345(oct31 4):e7186–e7186. doi:10.1136/bmj.e7186

21. Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol. 2011 May;12(5):441–50. doi:10.1016/S1470-2045(11)70078-X

22. Verhoef L, Bleeker MCG, Polman N, Kroon KR, Steenbergen RDM, Ebisch RMF, et al. Colposcopy referrals and CIN3 detection after triage by host cell DNA methylation and/or HPV genotyping in HPV positive women with low-grade cytology from a population-based Dutch primary HPV screening trial. Int J Cancer. 2025 Mar 16;156(5):1065–73. doi:10.1002/ijc.35289

23. Klausch T, Lissenberg-Witte BI, Coupé VM. A Bayesian prevalence-incidence mixture model for screening outcomes with misclassification. 2026 Jan 9.

Tables

Table 1. Power of the Gamma score test for different combinations of background risk (β), sample size (N) and shape parameter (k). Data sets were generated for each combination until 100 data sets had a successful model fit. The brackets show the number of data sets that were required to have 100 converged model fits for each simulation setting.

	N = 1000			N = 10000		
	k=1	k=1.5	k=2	k=1	k=1.5	k=2
Estimating β						
$\beta = 0.005$	0.09	0.11	0.84	0.05	1.00	1.00
$\beta = 0.01$	0.08	0.19	0.66	0.04	0.98	1.00
$\beta = 0.02$	0.07	0.11	0.48 (106)	0.05	0.96	1.00
Fixed β						
$\beta = 0$	0.04	0.47	0.99	0.05	1.00	1.00
$\beta = 0.005$	0.10	0.28	0.91	0.03	1.00	0.97
$\beta = 0.01$	0.08	0.11	0.61	0.04	0.97	0.85
$\beta = 0.02$	0.03	0.12	0.43	0.04	0.89	0.71

Table 2. Parameter estimates (95% confidence/credible intervals (CI/ CrI)) for the POBASCAM study application with and without the Cauchy prior

Parameter			Without priors or background risk — Estimate (95% CI)	Without priors, with background risk — Estimate (95% CI)	With priors, with background risk — Estimate (95% CrI)
Prevalence	Intercept	$\hat{\theta}_{1,0}$	-5.28 (-6.84, -3.73)	-12.83 (-519.75, 494.09)	-5.66 (-7.73, -3.59)
	Effect of HPV16	$\hat{\theta}_{1,1}$	1.22 (0.9, 1.54)	1.22 (0.89, 1.54)	1.21 (0.88, 1.53)
	Effect of abnormal cytology	$\hat{\theta}_{1,3}$	4.55 (2.99, 6.11)	12.09 (-494.83, 519.02)	4.93 (2.86, 7)
Progression	Intercept	$\hat{\theta}_{2,0}$	-3.4 (-3.59, -3.21)	-3.47 (-3.73, -3.21)	-3.5 (-3.78, -3.23)
	Effect of HPV16	$\hat{\theta}_{2,1}$	0.96 (0.74, 1.18)	1.23 (0.89, 1.56)	1.21 (0.87, 1.55)
Clearance		$\widehat{\lambda_2}$	-2.05 (-2.25, -1.85)	-1.58 (-1.97, -1.2)	-1.61 (-2.01, -1.21)
Log of background risk		$\log(\hat{\beta})$		--	-5.23 (-5.98, -4.49)
Log-likelihood			-2037.36	-2034.58	--
Gamma score test p-value			0.97	0.96	0.49

HPV16: human papillomavirus genotype 16

Table 3. Parameter estimates (95% confidence/credible intervals (CI/ CrI)) for the post-treatment surveillance data application with and without the Cauchy prior.

Parameter			Without priors or background risk Estimate (95% CI)	Without priors, with background risk Estimate (95% CI)	With priors, with background risk Estimate (95% CrI)
Prevalence	Intercept	$\hat{\theta}_{1,0}$	-3.60 (-5.35, -1.85)	-4.33 (-8.7, 0.04)	-3.6 (-5.21, -1.99)
	Effect of CIN3 [a]	$\hat{\theta}_{1,1}$	1.15 (-0.66, 2.95)	1.39 (-2.96, 5.74)	0.62 (-1.05, 2.29)
Progression	Intercept	$\hat{\theta}_{2,0}$	-3.41 (-4.31, -2.51)	-2.73 (-4.04, -1.42)	-2.73 (-3.8, -1.65)
	Effect of CIN3 [a]	$\hat{\theta}_{2,1}$	0.34 (-0.57, 1.25)	0.58 (-0.67, 1.83)	0.60 (-0.42, 1.62)
Clearance	Intercept	$\widehat{\lambda_2}$	-1.24 (-1.69, -0.78)	-0.20 (-0.77, 0.36)	-0.18 (-0.73, 0.37)
Log of background risk		$\log(\hat{\beta})$	--	-5.76 (-6.61, -4.91)	-5.71 (-6.53, -4.88)
Log-likelihood			-303.13	-298.88	--
Gamma score test p-value			0.0047	0.51	0.24

[a] Histology variable is original baseline diagnosis (CIN2 = 0, CIN3 = 1).

CIN2/3: cervical intraepithelial neoplasia grade 2/3

Figures

Figure 1. Simulation study results without covariates and with covariates for combinations of prior inclusion, sample size (N), attendance probability and value of background risk. Panels A and B show bias and coverage probability, respectively. Without covariates, parameters are prevalence ($\theta_{1,1}$), progression ($\theta_{2,1}$), clearance (λ_2), and background risk (β). With covariates, parameters are prevalence intercept ($\theta_{1,0}$), effect of age on prevalence ($\theta_{1,1}$), and effect of HPV16 on prevalence ($\theta_{1,2}$), progression intercept ($\theta_{2,0}$), effect of HPV16 on progression ($\theta_{2,1}$), clearance (λ_2), and background risk (β).